HLB Therapeutics KRX:115450KOSDAQ
HLB테라퓨틱스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked10since Sep 11
In Q2 2026, HLB Therapeutics reported revenue of ₩12.6bn, down 19.9% year on year, and an operating loss of ₩4.7bn. HLB Therapeutics (HLB테라퓨틱스) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 21 with 3 articles. The most common catalyst was clinical & approvals (1).
Filing signals Major holder adding Screener
HLB Therapeutics quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩12.6bn | -19.9% | −₩4.7bn margin −37.7% | −₩9.0bn |
| Q1 2026 | ₩13.0bn | -13.3% | −₩3.2bn margin −24.8% | −₩4.4bn |
| Q4 2025 derived | ₩22.8bn | +38.4% | ₩4.1bn margin 18.0% | ₩505m |
| Q3 2025 | ₩16.1bn | +14.3% | −₩5.4bn margin −33.5% | −₩5.6bn |
| Q2 2025 | ₩15.7bn | +34.4% | −₩666m margin −4.2% | −₩39m |
| Q1 2025 | ₩15.0bn | +18.0% | −₩1.6bn margin −10.5% | −₩4.5bn |
| Q4 2024 derived | ₩16.5bn | +5.1% | ₩16m margin 0.1% | ₩1.8bn |
| Q3 2024 | ₩14.1bn | -26.2% | −₩1.8bn margin −13.0% | −₩2.6bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
HLB Therapeutics top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4